A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
Completed
- Conditions
- Chronic Migraine, Headaches
- Registration Number
- NCT01749410
- Lead Sponsor
- Allergan
- Brief Summary
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- 15 or more headache days over a 30 day period
- A minimum of 7 treatment cycles with onabotulinumtoxinA
Exclusion Criteria
- Any treatment cycle dose of onabotulinumtoxinA greater than 200 units
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change From Baseline in the Number of Headache Days Treatment Cycle 7 (approximately 1.5 years) The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which onabotulinumtoxinA inhibits CGRP release in chronic migraine patients?
How does onabotulinumtoxinA compare to gepants and ditans in long-term migraine prevention efficacy?
Which biomarkers correlate with sustained response to botulinum neurotoxin type A in refractory chronic migraine cases?
What are the most common adverse events associated with repeated onabotulinumtoxinA injections for chronic migraines?
How do combination therapies of botulinum toxins with CGRP monoclonal antibodies affect migraine treatment outcomes?